Screener
CRISPR Therapeutics CRSP Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
FAQ
- What is CRISPR Therapeutics's current ratio?
- CRISPR Therapeutics (CRSP) reported current ratio of 18× in Q1 2026.
- How has CRISPR Therapeutics's current ratio changed year-over-year?
- CRISPR Therapeutics's current ratio increased by 14.9% year-over-year, from 15.6× to 18×.
- What is the long-term trend for CRISPR Therapeutics's current ratio?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's current ratio has grown at a -6.1% compound annual growth rate (CAGR), from 18.2× to 13.3×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about CRISPR Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude